N/A
Completed N=35
Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%
Source: ClinicalTrials.gov NCT00827255 ↗Enrolled (actual)
35
Serious AEs
—
Results posted
Jul 2012
Primary outcomePrimary: Percentage of Patients With Complete Clearing of Corneal Staining at Month 12 — 33.3 Percentage of Patients
Summary
The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients With Complete Clearing of Corneal Staining at Month 12 |
33.3 | — |
| SECONDARY Schirmer's Test at Month 12 |
— | — |
Eligibility Criteria
Inclusion Criteria
- Adults >16 years of age
- Dry eye patients
- Subject with history of less than 12 weeks of initial RESTASIS® treatment
- Subject started second trial of RESTASIS® treatment prior to June 1, 2008
- First day of second trial of RESTASIS® started ≥ 4 weeks after the last day of previous RESTASIS® treatment
Exclusion Criteria
- Patients with Contact Lens Intolerance
- Patients with Ocular Rosacea
Data sourced from ClinicalTrials.gov (NCT00827255). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.